Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current RCDTF market cap is 10.73B. The company's latest EPS is EUR 1.8953 and P/E is 27.57.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 1.45B | 1.42B | 1.54B | 1.84B | 2.07B |
| Operating Income | 464.06M | 469.02M | 490.19M | 437.33M | 558.01M |
| Net Income | 368.83M | 354.98M | 385.97M | 312.34M | 389.21M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 2.81B | 2.71B | 2.82B | 4B | 4.21B |
| Total Liabilities | 1.61B | 1.44B | 1.43B | 2.45B | 2.52B |
| Total Equity | 1.2B | 1.28B | 1.38B | 1.55B | 1.69B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 334.03M | 403.58M | 491.65M | 461.69M | 485.32M |
| Investing | -469.01M | -131.56M | -87.5M | -767.12M | -379.62M |
| Financing | 125.03M | -264.29M | -355.94M | 341.28M | -168.91M |
| Market Cap | 10.73B |
| Price to Earnings Ratio | 27.57 |
| Price to Sales Ratio | 5.19 |
| Price to Cash Ratio | 48.38 |
| Price to Book Ratio | 6.36 |
| Dividend Yield | 2.19% |
| Shares Outstanding | 205.36M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.52% |
| 52 Week High | 52.25 |
| 52 Week Low | 51.60 |
| Spread (Intraday) | 22.12k (99.85%) |
| Company Name | Recordati Industria Chimica e Farmaceutica Spa Mila Shares (PK) |
| Address |
via matteo civitali 1 milan, lombardy 20148 |
| Website | https://www.recordati.it |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
